A quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX Phosphorylation in human peripheral blood mononuclear cells

Oncoscience

Volumn 2, Issue 5, 2015, Pages 542-554

  Bakkenist, Christopher J ^a   Czambel, R Kenneth ^a   Hershberger, Pamela A ^b   Tawbi, Hussein ^a   Beumer, Jan H ^c   Schmitz, John C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

ATM; DNA damage response; Doxorubicin; H2AX; PBMCs

Indexed keywords

EID: 84953875950     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.162     Document Type: Article

References (35)

1. Srinivasan A, Wang L, Cline CJ, Xie Z, Sobol RW, Xie XQ and Gold B. Identification and characterization of human apurinic/apyrimidinic endonuclease-1 inhibitors. Biochemistry. 2012; 51(31):6246-6259.
2. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-917.
3. Turner N, Tutt A and Ashworth A. Targeting the DNA repair defect of BRCA tumours. Current opinion in pharmacology. 2005; 5(4):388-393.
4. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM, Jackson SP, Curtin NJ and Smith GC. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer research. 2004; 64(24):9152-9159.
5. Toledo LI, Murga M, Zur R, Soria R, Rodriguez A, Martinez S, Oyarzabal J, Pastor J, Bischoff JR and Fernandez-Capetillo O. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nature structural&molecular biology. 2011; 18(6):721-727.
6. Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, Golec JM and Pollard JR. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nature chemical biology. 2011; 7(7):428-430.
7. Foote KM, Blades K, Cronin A, Fillery S, Guichard SS, Hassall L, Hickson I, Jacq X, Jewsbury PJ, McGuire TM, Nissink JW, Odedra R, Page K, Perkins P, Suleman A, Tam K, et al. Discovery of 4-(4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-y l)-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. Journal of medicinal chemistry. 2013; 56(5):2125-2138.
8. Leahy JJ, Golding BT, Griffin RJ, Hardcastle IR, Richardson C, Rigoreau L and Smith GC. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorganic&medicinal chemistry letters. 2004; 14(24):6083-6087.
9. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH and de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England journal of medicine. 2009; 361(2):123-134.
10. Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. The Journal of biological chemistry. 1998; 273(10):5858-5868.
11. Sedelnikova OA, Pilch DR, Redon C and Bonner WM. Histone H2AX in DNA damage and repair. Cancer biology&therapy. 2003; 2(3):233-235.
12. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y and Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. The Journal of biological chemistry. 2000; 275(13):9390-9395.
13. Picariello L, Carbonell Sala S, Martineti V, Gozzini A, Aragona P, Tognarini I, Paglierani M, Nesi G, Brandi ML and Tonelli F. A comparison of methods for the analysis of low abundance proteins in desmoid tumor cells. Analytical biochemistry. 2006; 354(2):205-212.
14. White JS, Yue N, Hu J and Bakkenist CJ. The ATM kinase signaling induced by the low-energy beta-particles emitted by (33)P is essential for the suppression of chromosome aberrations and is greater than that induced by the energetic beta-particles emitted by (32)P. Mutation research. 2011; 708(1-2):28-36.
15. Bakkenist CJ and Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003; 421(6922):499-506.
16. White JS, Choi S and Bakkenist CJ. Irreversible chromosome damage accumulates rapidly in the absence of ATM kinase activity. Cell cycle. 2008; 7(9):1277-1284.
17. Stiff T, Walker SA, Cerosaletti K, Goodarzi AA, Petermann E, Concannon P, O'Driscoll M and Jeggo PA. ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. The EMBO journal. 2006; 25(24):5775-5782.
18. Cummings J, Raynaud F, Jones L, Sugar R and Dive C. Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. British journal of cancer. 2010; 103(9):1313-1317.
19. Zhang JH, Chung TD and Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. Journal of biomolecular screening. 1999; 4(2):67-73.
20. Marangon E, Sala F, Caffo O, Galligioni E, D'Incalci M and Zucchetti M. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry. Journal of mass spectrometry. 2008; 43(2):216-223.
21. Kroschinsky FP, Friedrichsen K, Mueller J, Pursche S, Haenel M, Prondzinsky R, Ehninger G and Schleyer E. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. Cancer chemotherapy and pharmacology. 2008; 61(5):785-790.
22. Chester JD, Joel SP, Cheeseman SL, Hall GD, Braun MS, Perry J, Davis T, Button CJ and Seymour MT. Phase I and pharmacokinetic study of intravenous irinotecan plus oral cyclosporin in patients with fluorouracil-refractory metastatic colon cancer. Journal of clinical oncology. 2003; 21(6):1125-1132.
23. Millward MJ, Webster LK, Rischin D, Stokes KH, Toner GC, Bishop JF, Olver IN, Linahan BM, Linsenmeyer ME and Woodcock DM. Phase I trial of cremophor EL with bolus doxorubicin. Clinical cancer research. 1998; 4(10):2321-2329.
24. Jones GG, Reaper PM, Pettitt AR and Sherrington PD. The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes. Oncogene. 2004; 23(10):1911-1921.
25. Sordet O, Redon CE, Guirouilh-Barbat J, Smith S, Solier S, Douarre C, Conti C, Nakamura AJ, Das BB, Nicolas E, Kohn KW, Bonner WM and Pommier Y. Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO reports. 2009; 10(8):887-893.
26. Chen T, Middleton FK, Falcon S, Reaper PM, Pollard JR and Curtin NJ. Development of pharmacodynamic biomarkers for ATR inhibitors. Molecular oncology. 2015; 9(2):463-472.
27. Yamashita A, Ohnishi T, Kashima I, Taya Y and Ohno S. Human SMG-1, a novel phosphatidylinositol 3-kinase-related protein kinase, associates with components of the mRNA surveillance complex and is involved in the regulation of nonsense-mediated mRNA decay. Genes&development. 2001; 15(17):2215-2228.
28. Brumbaugh KM, Otterness DM, Geisen C, Oliveira V, Brognard J, Li X, Lejeune F, Tibbetts RS, Maquat LE and Abraham RT. The mRNA surveillance protein hSMG-1 functions in genotoxic stress response pathways in mammalian cells. Molecular cell. 2004; 14(5):585-598.
29. Liu JH, Tang J, Lan XG, Liu YW, Li ZJ, Cheng F, Deng P and Jiang Y. [Application of two-color infrared fluorescence for detection of protein phosphorylation]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2006; 26(2):150-153.
30. Weldon S, Ambroz K, Schutz-Geschwender A and Olive DM. Near-infrared fluorescence detection permits accurate imaging of loading controls for Western blot analysis. Analytical biochemistry. 2008; 375(1):156-158.
31. Bakkenist CJ, Czambel RK, Clump DA, Greenberger JS, Beumer JH and Schmitz JC. Radiation therapy induces the DNA damage response in peripheral blood. Oncotarget. 2013; 4(8):1143-1148.
32. Sakamoto K, Hikiba Y, Nakagawa H, Hirata Y, Hayakawa Y, Kinoshita H, Nakata W, Sakitani K, Takahashi R, Akanuma M, Kamata H and Maeda S. Promotion of DNA repair by nuclear IKKbeta phosphorylation of ATM in response to genotoxic stimuli. Oncogene. 2013; 32(14):1854-1862.
33. Kurz EU, Douglas P and Lees-Miller SP. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. The Journal of biological chemistry. 2004; 279(51):53272-53281.
34. Towbin H, Staehelin T and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979. Biotechnology. 1992; 24:145-149.
35. Ji J, Kinders RJ, Zhang Y, Rubinstein L, Kummar S, Parchment RE, Tomaszewski JE and Doroshow JH. Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells. PloS one. 2011; 6(10):e26152.